mumps
Information
- Disease name
- mumps
- Disease ID
- DOID:10264
- Description
- "A viral infectious disease that results in inflammation located in salivary gland, has_material_basis_in Mumps rubulavirus, which is transmitted by droplet spread of saliva or mucus from the mouth, nose, or throat of an infected person, or transmitted by contaminated fomites. The infection has symptom fever, has symptom headache, has symptom muscle aches, has symptom tiredness, has symptom loss of appetite, has symptom swollen and tender salivary glands under the ears or jaw on one or both sides of the face." [url:http\://www.cdc.gov/mumps/about/downloads/mumps-factsheet.pdf]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT06208683 | Active, not recruiting | Phase 4 | The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students | November 4, 2023 | December 1, 2024 |
| NCT00092404 | Completed | Phase 2 | Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED) | December 2001 | June 2005 |
| NCT00092430 | Completed | Phase 3 | Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) | September 26, 2002 | June 9, 2003 |
| NCT00109343 | Completed | Phase 3 | V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019) | March 2006 | September 2007 |
| NCT00126997 | Completed | Phase 4 | Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases | May 2005 | November 2005 |
| NCT00127010 | Completed | Phase 3 | Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases | November 2005 | June 2006 |
| NCT00127023 | Completed | Phase 3 | Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases | May 2005 | November 2005 |
| NCT00156559 | Completed | MMR and Varicella Vaccine in Premature Infants | January 2004 | May 2005 | |
| NCT00388440 | Completed | Phase 4 | Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. | November 2000 | April 2001 |
| NCT01874457 | Completed | Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella) | May 2008 | August 2009 | |
| NCT01991899 | Completed | Phase 3 | Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. | February 2015 | July 2016 |
| NCT02058563 | Completed | Phase 3 | Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older | July 1, 2014 | September 17, 2015 |
| NCT02325310 | Completed | Phase 4 | Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR | February 4, 2015 | November 1, 2017 |
| NCT02692599 | Completed | Phase 3 | Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants | January 2016 | July 15, 2016 |
| NCT02880865 | Completed | Phase 4 | Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine | October 13, 2016 | July 11, 2017 |
| NCT03160820 | Completed | Phase 4 | Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine | March 2016 | February 2017 |
| NCT04364399 | Completed | Phase 4 | Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine | November 18, 2020 | April 7, 2021 |
| NCT05065177 | Completed | Phase 3 | Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants | January 2016 | April 2016 |
| NCT05145166 | Completed | Safety Study of Live Attenuated Mumps Vaccines in Junior High School Students Under 14 Years Old | October 6, 2020 | March 25, 2021 | |
| NCT00313950 | Completed | Phase 4 | Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine | September 2006 | April 2010 |
| NCT00326183 | Completed | Phase 4 | Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) | March 26, 2007 | January 15, 2008 |
| NCT00351923 | Completed | Phase 3 | Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes | March 2006 | December 2006 |
| NCT00352898 | Completed | Phase 2 | Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™ | April 2006 | November 2006 |
| NCT00353288 | Completed | Phase 2 | Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™ | March 2006 | November 2006 |
| NCT00384397 | Completed | Phase 3 | A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers | September 2006 | February 2009 |
| NCT00092391 | Completed | Phase 3 | A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED) | February 1999 | July 2001 |
| NCT00402831 | Completed | Phase 3 | ProQuad® Intramuscular vs Subcutaneous | October 6, 2006 | May 11, 2007 |
| NCT00406211 | Completed | Phase 3 | Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine | July 2004 | December 2004 |
| NCT00422292 | Completed | Phase 3 | Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers | December 2006 | April 2009 |
| NCT00432042 | Completed | Phase 3 | Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) | January 12, 2007 | March 27, 2008 |
| NCT00432523 | Completed | Phase 3 | Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011) | January 20, 2005 | September 5, 2005 |
| NCT00432731 | Completed | Phase 4 | Safety Study of a Refrigerator-stable Formulation of VARIVAX® | December 2004 | September 2005 |
| NCT00483574 | Completed | Phase 3 | Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers | May 2007 | April 2009 |
| NCT00560755 | Completed | Phase 3 | Safety Study of ProQuad® rHA in Infants (V221-037) | October 24, 2007 | November 24, 2008 |
| NCT00566527 | Completed | Phase 3 | Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) | November 29, 2007 | December 29, 2008 |
| NCT00578175 | Completed | Phase 2 | Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age | November 20, 2007 | March 17, 2009 |
| NCT00751348 | Completed | Phase 3 | Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136 | October 1, 2008 | May 27, 2010 |
| NCT00861744 | Completed | Phase 2 | Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age | June 3, 2009 | June 18, 2012 |
| NCT00892775 | Completed | Phase 2 | Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds | June 3, 2009 | December 13, 2010 |
| NCT00962819 | Completed | Measles, Mumps, and Rubella (MMR) Immunity in College Students | March 2010 | December 2012 | |
| NCT00969436 | Completed | Phase 3 | Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM | November 9, 2009 | February 21, 2011 |
| NCT00975507 | Completed | Phase 3 | ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) | March 1998 | June 1999 |
| NCT00984295 | Completed | Phase 3 | Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines | June 2000 | December 2001 |
| NCT00985153 | Completed | Phase 3 | Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) | March 2000 | May 2001 |
| NCT00985166 | Completed | Phase 3 | A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) | August 2000 | May 2003 |
| NCT00986232 | Completed | Phase 2 | ProQuad Dose Selection Study (V221-011)(COMPLETED) | April 1999 | September 2000 |
| NCT01188343 | Completed | Phase 3 | Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers | August 2010 | December 2012 |
| NCT01369394 | Completed | N/A | Making Decisions About the Measles-Mumps-Rubella Vaccine | June 2011 | July 2012 |
| NCT01390922 | Completed | Special Drug Use Investigation for Botox® (Botulinum) Spasticity (BOTOX is a Registered Trademark of Allergan, Inc.) | August 2011 | October 2014 | |
| NCT01506193 | Completed | Phase 3 | Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children | February 6, 2012 | March 31, 2014 |
| NCT01536405 | Completed | Phase 3 | Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) | June 5, 2012 | January 27, 2014 |
| NCT01681992 | Completed | Phase 3 | Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life | October 10, 2012 | August 18, 2015 |
| NCT01702428 | Completed | Phase 3 | Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age | November 9, 2012 | April 16, 2015 |
| NCT01712906 | Completed | Phase 1 | A Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Children | October 2012 | April 2013 |
| NCT01777529 | Completed | Phase 4 | Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations | October 2012 | December 2013 |
| NCT05952505 | Not yet recruiting | Phase 4 | Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine Coadministered With Two Attenuated Vaccines | August 2023 | December 2024 |
| NCT05894395 | Recruiting | Phase 3 | Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination | December 1, 2023 | September 1, 2025 |
| NCT06331702 | Recruiting | Phase 4 | Immunogenicity of Japanese Encephalitis Vaccine Co-administered With Measles-Mumps-Rubella Vaccine (MMR) | March 2, 2024 | December 31, 2024 |
| NCT00138255 | Terminated | Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines | June 2004 | June 2005 | |
| NCT00258726 | Terminated | Phase 1/Phase 2 | Immune Responses to Two Dose Varivax +/- MMR-II | October 2005 | July 2007 |
| NCT00839917 | Terminated | Phase 3 | A Study of ProQuad™ in Healthy Children in Korea (V221-023) | February 2008 | May 2008 |
| NCT00645996 | Unknown status | N/A | The Influence of Probiotics on the Immunologic Response to Vaccinations in Infants | March 2008 | October 2009 |
| NCT05279248 | Unknown status | Phase 4 | The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine | August 25, 2021 | June 20, 2023 |
| NCT00932269 | Unknown status | Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease | March 2007 | September 2011 | |
| NCT01738841 | Withdrawn | Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines | August 2013 | March 2016 |
- Disase is a (Disease Ontology)
- DOID:934
- Cross Reference ID (Disease Ontology)
- GARD:7116
- Cross Reference ID (Disease Ontology)
- ICD10CM:B26
- Cross Reference ID (Disease Ontology)
- ICD9CM:072
- Cross Reference ID (Disease Ontology)
- MESH:D009107
- Cross Reference ID (Disease Ontology)
- NCI:C29888
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:154352008
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0026780
- ICD10 preferred id (Insert disease from ICD10)
- D0000581
- ICD10 class code (Insert disease from ICD10)
- B26
- MeSH unique ID (MeSH (Medical Subject Headings))
- D009107